Skip Nav Destination
Issues
Acta Haematologica 2015, Vol. 134, No. 3
Editorial Comment
Immunosuppressive Therapy in Myelodysplastic Syndromes Is Still Alive
Acta Haematol (2015) 134 (3): 135–137.
https://doi.org/10.1159/000371833
Original Paper
Cyclosporine Combined with Levamisole for Lower-Risk Myelodysplastic Syndromes
Xingxin Li; Jun Shi; Min Wang; Neng Nie; Yingqi Shao; Meili Ge; Jinbo Huang; Zhendong Huang; Jing Zhang; Yizhou Zheng
Acta Haematol (2015) 134 (3): 138–145.
https://doi.org/10.1159/000370097
Atovaquone for Prophylaxis of Toxoplasmosis after Allogeneic Hematopoietic Stem Cell Transplantation
Alexander Mendorf; Evgeny Klyuchnikov; Claudia Langebrake; Holger Rohde; Francis Ayuk; Marc Regier; Maximilian Christopeit; Tatjana Zabelina; Adelbert Bacher; Thomas Stübig; Christine Wolschke; Ulrike Bacher; Nicolaus Kröger
Acta Haematol (2015) 134 (3): 146–154.
https://doi.org/10.1159/000380757
Case Report
Lymphoproliferative Disorders in Patients with Chronic Myeloid Leukemia: A Single-Center Case Series
Acta Haematol (2015) 134 (3): 161–167.
https://doi.org/10.1159/000375150
Editorial Comment
Rituximab in Thrombotic Thrombocytopenic Purpura: Medical and Financial Benefits
Acta Haematol (2015) 134 (3): 168–169.
https://doi.org/10.1159/000381413
Original Paper
A 14-Year Experience in the Management of Patients with Acquired Immune Thrombotic Thrombocytopenic Purpura in Northern Israel: Rituximab Adjuvant Therapy in Patients with Refractory and Relapsed Disease Is Both Effective and Cost Beneficial
Nadav Rinott; Tatiana Mashiach; Netanel A. Horowitz; Liliana Schliamser; Galit Sarig; Anat Keren-Politansky; Eldad J. Dann
Acta Haematol (2015) 134 (3): 170–176.
https://doi.org/10.1159/000371867
Brief Communication
The Prevalence and Biochemical Profiles of EDTA-Dependent Pseudothrombocytopenia in a Generally Healthy Population
Acta Haematol (2015) 134 (3): 177–180.
https://doi.org/10.1159/000373915
Two Cases of Successful Autologous Hematopoietic Stem Cell Harvest after Treatment with Brentuximab Vedotin
Minoru Kojima; Daisuke Ogiya; Hidetsugu Kawai; Mitsuki Miyamoto; Ken Ohmachi; Yoshiaki Ogawa; Naoya Nakamura; Kiyoshi Ando
Acta Haematol (2015) 134 (3): 181–182.
https://doi.org/10.1159/000371834
Thalassemia Major: Who Is Afraid of Serum Ferritin below 500 μg/l?
Francesca Pinna; Roberto Carta; Maddalena Morittu; Carlo Dessì; Paolo Moi; GianBattista Leoni; Maria Loreta Foschini; Elisabetta Defraia; Antonietta Zappu; Raffaella Origa
Acta Haematol (2015) 134 (3): 183–184.
https://doi.org/10.1159/000371866
Editorial Comment
What Is the Role of Rituximab in Nodular Lymphocyte-Predominant Hodgkin Lymphoma?
Acta Haematol (2015) 134 (3): 185–186.
https://doi.org/10.1159/000381765
Original Paper
Can Rituximab Improve the Outcome of Patients with Nodular Lymphocyte-Predominant Hodgkin's Lymphoma?
Heidi Mocikova; Robert Pytlik; Pavla Stepankova; Jozef Michalka; Jana Markova; Jan Koren; Lucie Buresova; Ludek Raida; Zdenek Kral
Acta Haematol (2015) 134 (3): 187–192.
https://doi.org/10.1159/000381327
